165 related articles for article (PubMed ID: 35578785)
41. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
42. The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks.
Bombarde O; Larminat F; Gomez D; Frit P; Racca C; Gomes B; Guilbaud N; Calsou P
Mol Cancer Ther; 2017 Oct; 16(10):2166-2177. PubMed ID: 28611105
[TBL] [Abstract][Full Text] [Related]
43. [Molecular determinants of response to topoisomerase II inhibitors].
Lansiaux A; Pourquier P
Bull Cancer; 2011 Nov; 98(11):1299-310. PubMed ID: 22023806
[TBL] [Abstract][Full Text] [Related]
44. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage.
Adachi N; Iiizumi S; So S; Koyama H
Biochem Biophys Res Commun; 2004 Jun; 318(4):856-61. PubMed ID: 15147950
[TBL] [Abstract][Full Text] [Related]
45. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
[TBL] [Abstract][Full Text] [Related]
46. Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology.
Ahmed SM; Dröge P
Mol Oncol; 2019 Oct; 13(10):2062-2078. PubMed ID: 31271486
[TBL] [Abstract][Full Text] [Related]
47. Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.
Zhao H; Rybak P; Dobrucki J; Traganos F; Darzynkiewicz Z
Cytometry A; 2012 Jan; 81(1):45-51. PubMed ID: 22140093
[TBL] [Abstract][Full Text] [Related]
48. Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast.
Stantial N; Rogojina A; Gilbertson M; Sun Y; Miles H; Shaltz S; Berger J; Nitiss KC; Jinks-Robertson S; Nitiss JL
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26876-26884. PubMed ID: 33046655
[TBL] [Abstract][Full Text] [Related]
49. MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner.
Shu J; Jiang J; Wang X; Yang X; Zhao G; Cai T
Cell Death Dis; 2024 Jan; 15(1):83. PubMed ID: 38263255
[TBL] [Abstract][Full Text] [Related]
50. ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms.
Shu J; Wang X; Yang X; Zhao G
Sci Rep; 2023 Jan; 13(1):882. PubMed ID: 36650267
[TBL] [Abstract][Full Text] [Related]
51. Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2·DNA and Top2·RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2).
Gao R; Schellenberg MJ; Huang SY; Abdelmalak M; Marchand C; Nitiss KC; Nitiss JL; Williams RS; Pommier Y
J Biol Chem; 2014 Jun; 289(26):17960-9. PubMed ID: 24808172
[TBL] [Abstract][Full Text] [Related]
52. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
53. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
Jannatipour M; Liu YX; Nitiss JL
J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
[TBL] [Abstract][Full Text] [Related]
54. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
Bau JT; Kurz EU
Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
[TBL] [Abstract][Full Text] [Related]
55. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
[TBL] [Abstract][Full Text] [Related]
56. Sensitivity to TOP2 targeting chemotherapeutics is regulated by Oct1 and FILIP1L.
Lu H; Hallstrom TC
PLoS One; 2012; 7(8):e42921. PubMed ID: 22900064
[TBL] [Abstract][Full Text] [Related]
57. Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA.
Morimoto S; Tsuda M; Bunch H; Sasanuma H; Austin C; Takeda S
Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31671674
[TBL] [Abstract][Full Text] [Related]
58. Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity.
Canela A; Maman Y; Huang SN; Wutz G; Tang W; Zagnoli-Vieira G; Callen E; Wong N; Day A; Peters JM; Caldecott KW; Pommier Y; Nussenzweig A
Mol Cell; 2019 Jul; 75(2):252-266.e8. PubMed ID: 31202577
[TBL] [Abstract][Full Text] [Related]
59. Mre11 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage Complexes.
Hoa NN; Shimizu T; Zhou ZW; Wang ZQ; Deshpande RA; Paull TT; Akter S; Tsuda M; Furuta R; Tsutsui K; Takeda S; Sasanuma H
Mol Cell; 2016 Nov; 64(3):580-592. PubMed ID: 27814490
[TBL] [Abstract][Full Text] [Related]
60. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]